Publications by authors named "A O Damiao"
Background: Despite adequate treatment, a subgroup of patients with inflammatory bowel disease (IBD), including Crohn`s disease and ulcerative colitis, have persistent gastrointestinal symptoms that are not always related to mucosal damage. Recently, two autoantibodies, anti-CdtB and anti-vinculin, were validated as post-infectious IBS (PI-IBS) markers, however there is limited evidence of its diagnostic role in IBD population.
Methods: Patients with more than 3 bowel movements/day and indication of colonoscopy were enrolled.
Article Synopsis
- Antibiotics are essential for treating infections and preventing illness, but their use, especially in infants, can lead to long-term health issues due to changes in gut microbiota.
- The disruption of gut microbiota, known as gut dysbiosis, is linked to various chronic diseases like obesity, diabetes, autoimmune disorders, and some cancers.
- Probiotics may help counteract the negative effects of gut dysbiosis in patients with chronic diseases, potentially improving their health and inflammation markers.
Patient-Related Factors Associated With Long-Term Outcomes After Successful Endoscopic Balloon Dilation For Crohn's Disease-Associated Ileo-Colic Strictures: A Systematic Review and Meta-analysis.
Crohns Colitis 360
July 2024
Background: Successful Crohn's disease (CD) therapy relies on timely and precise management strategies. Endoscopic balloon dilation (EBD) has been applied as a first-line treatment for symptomatic CD-associated strictures due to its minimally invasive nature and the possibility of preserving intestinal length.
Objective: The aim of the present study was to determine patient-related predictive factors associated with the need for surgery for CD-associated ileocolic strictures after technically successful EBD.
Imbalanced dietary intake is associated with the development of inflammatory bowel diseases (IBDs) and is often observed during the active phases of Crohn's disease (CD) and ulcerative colitis (UC). Cumulative data also suggest the potential for dietary manipulation in avoiding IBD relapse. However, there is a paucity of dietary data from patients in clinical remission to guide such an approach.
View Article and Find Full Text PDFArticle Synopsis
- Biological therapies, like Infliximab (IFX), are key for treating inflammatory bowel disease (IBD) but some patients either don't respond or lose effectiveness over time, necessitating research into factors influencing treatment outcomes.
- The study aimed to identify predictors of clinical and endoscopic remission in IBD patients receiving IFX in Brazil, utilizing a cross-sectional approach to gather demographic and clinical data.
- Results showed that 79.4% experienced clinical remission while 58.2% had endoscopic remission; factors like the duration of IFX therapy and albumin levels were linked to better outcomes, while previous surgeries and certain prior treatments negatively impacted remission chances.